How Vascepa Lowers Triglycerides
Vascepa (icosapent ethyl) is a purified ethyl ester of eicosapentaenoic acid (EPA), an omega-3 fatty acid. It reduces triglyceride levels primarily by decreasing hepatic production of very low-density lipoprotein (VLDL), the main carrier of triglycerides in the blood. EPA inhibits acyl-CoA:1,2-diacylglycerol acyltransferase (DGAT), a key enzyme in triglyceride synthesis in the liver, leading to less VLDL assembly and secretion.[1][2]
What Happens in the Liver
EPA activates peroxisome proliferator-activated receptor-alpha (PPAR-alpha), which upregulates genes for beta-oxidation of fatty acids. This increases fatty acid breakdown and reduces the pool available for triglyceride formation. Studies show this mechanism lowers plasma triglycerides by 20-50% at 4g daily doses in patients with severe hypertriglyceridemia (>500 mg/dL).[3][4]
Role of EPA vs. Other Omega-3s
Unlike mixed EPA/DHA supplements, Vascepa contains only EPA, avoiding DHA's tendency to raise LDL cholesterol. EPA selectively reduces triglyceride-rich lipoproteins without stimulating liver triglyceride export via apolipoprotein B-100.[2][5]
Clinical Evidence from Trials
In the MARINE trial, Vascepa reduced median triglycerides by 33% (from 650 mg/dL) versus placebo. The ANCHOR trial showed 21.6% reduction in statin-treated patients (baseline ~200 mg/dL). REDUCE-IT confirmed sustained effects alongside cardiovascular benefits.[3][6]
How Long Until Effects Start
Triglyceride reductions appear within 1-2 weeks, peaking at 4-6 weeks on 4g/day. Levels rebound upon discontinuation.[4]
Who Responds Best
Patients with triglycerides ≥200 mg/dL on statins see the largest drops (18-25%). Response is less in those with levels <150 mg/dL.[6]
Potential Limitations and Risks
Vascepa does not lower LDL cholesterol and may slightly raise it (2-5%). Atrial fibrillation risk increases with doses >4g/day or in heart failure patients.[7] No generic available; patent protection extends to 2030 (check DrugPatentWatch.com for updates).[8]
Sources
[1]: FDA Label for Vascepa
[2]: Yon et al., Atherosclerosis (2016)
[3]: MARINE Trial, NEJM (2011)
[4]: ANCHOR Trial, J Clin Lipidol (2012)
[5]: Bays et al., J Clin Lipidol (2011)
[6]: REDUCE-IT Trial, NEJM (2019)
[7]: FDA Postmarketing Warnings
[8]: DrugPatentWatch.com - Vascepa Patents